Development of new vaccines and drugs for TB: limitations and potential strategic errors

Papers of special note have been highlighted as: ▪ of interest

Bibliography

• 1  Glaziou P, Floyd K, Raviglione M: Global burden and epidemiology of tuberculosis. Clin. Chest Med.30,621–636 (2009).
  MedlineGoogle Scholar
• 2  Bifani PJ, Mathema B, Kurepina NE, Kreiswirth BN: Global dissemination of the Mycobacterium tuberculosis W-Beijing family strains. Trends Microbiol.10,45–52 (2002).
  Medline CASGoogle Scholar
• 3  Wright A, Zignol M, Van Deun A et al.: Epidemiology of antituberculosis drug resistance 2002–2007: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet373(9678),1861–1873 (2009).
  MedlineGoogle Scholar
• 4  Velayati AA, Masjedi MR, Farnia P et al.: Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest136,420–425 (2009).
  MedlineGoogle Scholar
• 5  Dye C: Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis. Nat. Rev. Microbiol.7,81–87 (2009).
  Medline CASGoogle Scholar
• 6  Dye C, Espinal MA: Will tuberculosis become resistant to all antibiotics? Proc. Biol. Sci.268,45–52 (2001).
  Medline CASGoogle Scholar
• 7  Fauci AS: Multidrug-resistant and extensively drug-resistant tuberculosis: the National Institute of Allergy and Infectious Diseases Research agenda and recommendations for priority research. J. Infect. Dis.197,1493–1498 (2008).▪ Comprehensive set of recommendations for basic and applied research on the multidrug-resistant/extensively drug-resistant strains.
  MedlineGoogle Scholar
• 8  Wells CD, Cegielski JP, Nelson LJ et al.: HIV infection and multidrug-resistant tuberculosis: the perfect storm. J. Infect. Dis.196(Suppl. 1),S86–S107 (2007).
  MedlineGoogle Scholar
• 9  Nunn P, Reid A, De Cock KM: Tuberculosis and HIV infection: the global setting. J. Infect. Dis.196(Suppl. 1),S5–S14 (2007).
  MedlineGoogle Scholar
• 10  Day JH, Grant AD, Fielding KL et al.: Does tuberculosis increase HIV load? J. Infect. Dis.190,1677–1684 (2004).
  MedlineGoogle Scholar
• 11  Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, Ellner J: Accelerated course of human immunodeficiency virus infection after tuberculosis. Am. J. Respir. Crit. Care Med.151,129–135 (1995).
  Medline CASGoogle Scholar
• 12  Rajbhandary SS, Marks SM, Bock NN: Costs of patients hospitalized for multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis.8,1012–1016 (2004).
  Medline CASGoogle Scholar
• 13  White VL, Moore-Gillon J: Resource implications of patients with multidrug resistant tuberculosis. Thorax55,962–963 (2000).
  Medline CASGoogle Scholar
• 14  Bock NN, Jensen PA, Miller B, Nardell E: Tuberculosis infection control in resource-limited settings in the era of expanding HIV care and treatment. J. Infect. Dis.196(Suppl.1),S108–S113 (2007).
  MedlineGoogle Scholar
• 15  Quy HT, Buu TN, Cobelens FG, Lan NT, Lambregts CS, Borgdorff MW: Drug resistance among smear-positive tuberculosis patients in Ho Chi Minh City, Vietnam. Int. J. Tuberc. Lung Dis.10,160–166 (2006).
  Medline CASGoogle Scholar
• 16  Dye C, Lonnroth K, Jaramillo E, Williams BG, Raviglione M: Trends in tuberculosis incidence and their determinants in 134 countries. Bull. World Health Organ.87,683–691 (2009).
  Medline CASGoogle Scholar
• 17  Gandhi NR, Moll A, Sturm AW et al.: Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet368,1575–1580 (2006).
  MedlineGoogle Scholar
• 18  Migliori GB, Sotgiu G: XDR tuberculosis in South Africa: old questions, new answers. Lancet375,1760–1761 (2010).
  MedlineGoogle Scholar
• 19  Kliiman K, Altraja A: Predictors of extensively drug-resistant pulmonary tuberculosis. Ann. Intern. Med.150,766–775 (2009).
  MedlineGoogle Scholar
• 20  Cooper AM: Cell-mediated immune responses in tuberculosis. Annu. Rev. Immunol.27,393–422 (2009).▪ Excellent overview of current knowledge of TB.
  Medline CASGoogle Scholar
• 21  North RJ: T cell dependence of macrophage activation and mobilization during infection with Mycobacterium tuberculosis. Infect. Immun.10,66–71 (1974).
  Medline CASGoogle Scholar
• 22  Johnson CM, Cooper AM, Frank AA, Orme IM: Adequate expression of protective immunity in the absence of granuloma formation in Mycobacterium tuberculosis-infected mice with a disruption in the intracellular adhesion molecule 1 gene. Infect. Immun.66,1666–1670 (1998).
  Medline CASGoogle Scholar
• 23  Orme IM, Collins FM: Protection against Mycobacterium tuberculosis infection by adoptive immunotherapy. Requirement for T cell-deficient recipients. J. Exp. Med.158,74–83 (1983).
  Medline CASGoogle Scholar
• 24  Orme IM: The kinetics of emergence and loss of mediator T lymphocytes acquired in response to infection with Mycobacterium tuberculosis. J. Immunol.138,293–298 (1987).
  Medline CASGoogle Scholar
• 25  Junqueira-Kipnis AP, Kipnis A, Jamieson A et al.: NK cells respond to pulmonary infection with Mycobacterium tuberculosis, but play a minimal role in protection. J. Immunol.171,6039–6045 (2003).
  Medline CASGoogle Scholar
• 26  Lockhart E, Green AM, Flynn JL: IL-17 production is dominated by γδ T cells rather than CD4 T cells during Mycobacterium tuberculosis infection. J. Immunol.177,4662–4669 (2006).
  Medline CASGoogle Scholar
• 27  D’Souza CD, Cooper AM, Frank AA, Mazzaccaro RJ, Bloom BR, Orme IM: An anti-inflammatory role for γ δ T lymphocytes in acquired immunity to Mycobacterium tuberculosis. J. Immunol.158,1217–1221 (1997).
  MedlineGoogle Scholar
• 28  Khader SA, Cooper AM: IL-23 and IL-17 in tuberculosis. Cytokine41,79–83 (2008).
  Medline CASGoogle Scholar
• 29  Ordway D, Henao-Tamayo M, Harton M et al.: The hypervirulent Mycobacterium tuberculosis strain HN878 induces a potent Th1 response followed by rapid down-regulation. J. Immunol.179,522–531 (2007).▪ First evidence that virulent clinical strains are potent inducers of regulatory T cells.
  Medline CASGoogle Scholar
• 30  Einarsdottir T, Lockhart E, Flynn JL: Cytotoxicity and secretion of γ interferon are carried out by distinct CD8 T cells during Mycobacterium tuberculosis infection. Infect. Immun.77,4621–4630 (2009).
  Medline CASGoogle Scholar
• 31  Flynn JL, Goldstein MM, Triebold KJ, Koller B, Bloom BR: Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc. Natl Acad. Sci. USA89,12013–12017 (1992).
  Medline CASGoogle Scholar
• 32  Wu Y, Woodworth JS, Shin DS, Morris S, Behar SM: Vaccine-elicited 10-kilodalton culture filtrate protein-specific CD8⁺ T cells are sufficient to mediate protection against Mycobacterium tuberculosis infection. Infect. Immun.76,2249–2255 (2008).
  Medline CASGoogle Scholar
• 33  Turner J, D’Souza CD, Pearl JE et al.: CD8- and CD95/95L-dependent mechanisms of resistance in mice with chronic pulmonary tuberculosis. Am. J. Respir. Cell. Mol. Biol.24,203–209 (2001).
  Medline CASGoogle Scholar
• 34  Gonzalez-Juarrero M, Turner OC, Turner J, Marietta P, Brooks JV, Orme IM: Temporal and spatial arrangement of lymphocytes within lung granulomas induced by aerosol infection with Mycobacterium tuberculosis. Infect. Immun.69,1722–1728 (2001).
  Medline CASGoogle Scholar
• 35  Orme I, Gonzalez-Juarrero M: Animal models of M. tuberculosis infection. Curr. Protoc. Microbiol. Chapter 10, Unit 10A.5 (2007).
  MedlineGoogle Scholar
• 36  Young D: Animal models of tuberculosis. Eur.J. Immunol.39,2011–2014 (2009).
  Medline CASGoogle Scholar
• 37  Flynn JL, Chan J: Immunology of tuberculosis. Annu. Rev. Immunol.19,93–129 (2001).
  Medline CASGoogle Scholar
• 38  Orme IM: Preclinical testing of new vaccines for tuberculosis: a comprehensive review. Vaccine24,2–19 (2006).
  MedlineGoogle Scholar
• 39  Kondratieva EV, Evstifeev VV, Kondratieva TK et al.: I/St mice hypersusceptible to Mycobacterium tuberculosis are resistant to M. avium. Infect. Immun.75,4762–4768 (2007).
  Medline CASGoogle Scholar
• 40  Pichugin AV, Yan BS, Sloutsky A, Kobzik L, Kramnik I: Dominant role of the sst1 locus in pathogenesis of necrotizing lung granulomas during chronic tuberculosis infection and reactivation in genetically resistant hosts. Am. J. Pathol.174,2190–2201 (2009).
  Medline CASGoogle Scholar
• 41  Sugawara I, Udagawa T, Yamada H: Rat neutrophils prevent the development of tuberculosis. Infect. Immun.72,1804–1806 (2004).
  Medline CASGoogle Scholar
• 42  Sugawara I, Yamada H, Mizuno S: Nude rat (F344/N-rnu) tuberculosis. Cell Microbiol.8,661–667 (2006).
  Medline CASGoogle Scholar
• 43  Tsenova L, Ellison E, Harbacheuski R et al.: Virulence of selected Mycobacterium tuberculosis clinical isolates in the rabbit model of meningitis is dependent on phenolic glycolipid produced by the bacilli. J. Infect. Dis.192,98–106 (2005).
  MedlineGoogle Scholar
• 44  Manabe YC, Dannenberg AM Jr, Tyagi SK et al.: Different strains of Mycobacterium tuberculosis cause various spectrums of disease in the rabbit model of tuberculosis. Infect. Immun.71,6004–6011 (2003).
  Medline CASGoogle Scholar
• 45  Buddle BM, Skinner MA, Wedlock DN, de Lisle GW, Vordermeier HM, Hewinson RG: Cattle as a model for development of vaccines against human tuberculosis. Tuberculosis (Edinb.)85,19–24 (2005).
  Medline CASGoogle Scholar
• 46  Orme IM: Immunology and vaccinology of tuberculosis: can lessons from the mouse be applied to the cow? Tuberculosis (Edinb.)81,109–113 (2001).
  Medline CASGoogle Scholar
• 47  Basaraba RJ: Experimental tuberculosis: the role of comparative pathology in the discovery of improved tuberculosis treatment strategies. Tuberculosis (Edinb.)88(Suppl. 1),S35–S47 (2008).▪ Comprehensive description of the pathology of TB in the relevant guinea pig model.
  MedlineGoogle Scholar
• 48  McMurray DN: Determinants of vaccine-induced resistance in animal models of pulmonary tuberculosis. Scand. J. Infect. Dis.33,175–178 (2001).
  Medline CASGoogle Scholar
• 49  McMurray DN, Collins FM, Dannenberg AM Jr, Smith DW: Pathogenesis of experimental tuberculosis in animal models. Curr. Top. Microbiol. Immunol.215,157–179 (1996).
  Medline CASGoogle Scholar
• 50  Basaraba RJ, Orme IM: Pulmonary tuberculosis in the guinea pig. In: A Color Atlas of Comparative Pathology of Pulmonary Tuberculosis. Leong FJ, Dartois V, Dick T (Eds). CRC Press, LA, USA 131–155 (2010).
  Google Scholar
• 51  Ly LH, Russell MI, McMurray DN: Cytokine profiles in primary and secondary pulmonary granulomas of Guinea pigs with tuberculosis. Am. J. Respir. Cell. Mol. Biol.38,455–462 (2008).
  Medline CASGoogle Scholar
• 52  Ordway D, Palanisamy G, Henao-Tamayo M et al.: The cellular immune response to Mycobacterium tuberculosis infection in the guinea pig. J. Immunol.179,2532–2541 (2007).
  Medline CASGoogle Scholar
• 53  Turner OC, Basaraba RJ, Frank AA, Orme IM: Granuloma formation in mouse and guinea pig models of experimental tuberculosis. In: Granulomatous Infections and Inflammation: Cellular and Molecular Mechanisms. Boros DL (Ed.). ASM Press, Washington, DC, USA 65–84 (2003).
  Google Scholar
• 54  Turner OC, Basaraba RJ, Orme IM: Immunopathogenesis of pulmonary granulomas in the guinea pig after infection with Mycobacterium tuberculosis. Infect. Immun.71,864–871 (2003).
  Medline CASGoogle Scholar
• 55  Williams A, Hall Y, Orme IM: Evaluation of new vaccines for tuberculosis in the guinea pig model. Tuberculosis (Edinb.)89,389–397 (2009).
  Medline CASGoogle Scholar
• 56  Ordway DJ, Shanley CA, Caraway ML et al.: Evaluation of standard chemotherapy in the guinea pig model of tuberculosis. Antimicrob. Agents Chemother.54,1820–1833 (2010).
  Medline CASGoogle Scholar
• 57  Capuano SV, Croix DA, Pawar S et al.: Experimental Mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the various manifestations of human M. tuberculosis infection. Infect. Immun.71,5831–5844 (2003).
  Medline CASGoogle Scholar
• 58  Walsh GP, Tan EV, de la Cruz EC et al.: The Philippine cynomolgus monkey (Macaca fasicularis) provides a new nonhuman primate model of tuberculosis that resembles human disease. Nat. Med.2,430–436 (1996).
  Medline CASGoogle Scholar
• 59  Lin PL, Rodgers M, Smith L et al.: Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model. Infect. Immun.77,4631–4642 (2009).
  Medline CASGoogle Scholar
• 60  Langermans JA, Doherty TM, Vervenne RA et al.: Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine23,2740–2750 (2005).
  Medline CASGoogle Scholar
• 61  Sharpe SA, McShane H, Dennis MJ et al.: Establishment of an aerosol challenge model of tuberculosis in rhesus macaques and an evaluation of endpoints for vaccine testing. Clin. Vaccine Immunol.17,1170–1182 (2010).▪ First defined low-dose aerosol infection model in nonhuman primate.
  Medline CASGoogle Scholar
• 62  Tobin DM, Vary JC Jr, Ray JP et al.: The lta4h locus modulates susceptibility to mycobacterial infection in zebrafish and humans. Cell140,717–730 (2010).
  Medline CASGoogle Scholar
• 63  Rhoades ER, Frank AA, Orme IM: Progression of chronic pulmonary tuberculosis in mice aerogenically infected with virulent Mycobacterium tuberculosis. Tuber. Lung Dis.78,57–66 (1997).
  Medline CASGoogle Scholar
• 64  Chackerian AA, Alt JM, Perera TV, Dascher CC, Behar SM: Dissemination of Mycobacterium tuberculosis is influenced by host factors and precedes the initiation of T-cell immunity. Infect. Immun.70,4501–4509 (2002).
  Medline CASGoogle Scholar
• 65  Wolf AJ, Desvignes L, Linas B et al.: Initiation of the adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the local lymph node, not the lungs. J. Exp. Med.205,105–115 (2008).
  Medline CASGoogle Scholar
• 66  Pedrosa J, Saunders BM, Appelberg R, Orme IM, Silva MT, Cooper AM: Neutrophils play a protective nonphagocytic role in systemic Mycobacterium tuberculosis infection of mice. Infect. Immun.68,577–583 (2000).
  Medline CASGoogle Scholar
• 67  Dannenberg AM: Immunopathogenesis of pulmonary tuberculosis. Hosp. Pract.28,51–58 (1993).
  Google Scholar
• 68  Dannenberg AM: Roles of cytotoxic delayed-type hypersensitivity and macrophage-activating cell-mediated immunity in the pathogenesis of tuberculosis. Immunobiology191,461–473 (1994).
  MedlineGoogle Scholar
• 69  Russell DG, Barry CE, Flynn JL: Tuberculosis: what we don’t know can, and does, hurt us. Science28,852–856 (2010).
  Google Scholar
• 70  Basaraba RJ, Smith EE, Shanley CA, Orme IM: Pulmonary lymphatics are primary sites of Mycobacterium tuberculosis infection in guinea pigs infected by aerosol. Infect. Immun.74,5397–5401 (2006).
  Medline CASGoogle Scholar
• 71  Lenaerts AJ, Hoff D, Aly S et al.: Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910. Antimicrob. Agents Chemother.51,3338–3345 (2007).
  Medline CASGoogle Scholar
• 72  Ryan GJ, Hoff DR, Driver ER et al.: Multiple M. tuberculosis phenotypes in mouse and guinea pig lung tissue revealed by a dual-staining approach. PLoS ONE5,E11108 (2010).
  MedlineGoogle Scholar
• 73  Via LE, Lin PL, Ray SM et al.: Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect. Immun.76,2333–2340 (2008).
  Medline CASGoogle Scholar
• 74  Rustad TR, Sherrid AM, Minch KJ, Sherman DR: Hypoxia: a window into Mycobacterium tuberculosis latency. Cell Microbiol.11,1151–1159 (2009).
  Medline CASGoogle Scholar
• 75  Dye C, Williams BG: The population dynamics and control of tuberculosis. Science328,856–861 (2010).
  Medline CASGoogle Scholar
• 76  Lienhardt C, Vernon A, Raviglione MC: New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes. Curr. Opin. Pulm. Med.16,186–193 (2010).
  Medline CASGoogle Scholar
• 77  Kliiman K, Altraja A: Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB. Eur. Respir. J.33,1085–1094 (2009).
  Medline CASGoogle Scholar
• 78  Mak A, Thomas A, Del Granado M, Zaleskis R, Mouzafarova N, Menzies D: Influence of multidrug resistance on tuberculosis treatment outcomes with standardized regimens. Am. J. Respir. Crit. Care Med.178,306–312 (2008).
  MedlineGoogle Scholar
• 79  Ginsberg AM, Spigelman M: Challenges in tuberculosis drug research and development. Nat. Med.13,290–294 (2007).
  Medline CASGoogle Scholar
• 80  Lenaerts AJ, Degroote MA, Orme IM: Preclinical testing of new drugs for tuberculosis: current challenges. Trends Microbiol.16,48–54 (2008).
  Medline CASGoogle Scholar
• 81  Nuermberger EL, Yoshimatsu T, Tyagi S et al.: Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am. J. Respir. Crit. Care Med.169,421–426 (2004).
  MedlineGoogle Scholar
• 82  Dorman SE, Johnson JL, Goldberg S et al.: Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am. J. Respir. Crit. Care Med.180,273–280 (2009).
  Medline CASGoogle Scholar
• 83  Brooks JV, Furney SK, Orme IM: Metronidazole therapy in mice infected with tuberculosis. Antimicrob. Agents Chemother.43,1285–1288 (1999).
  Medline CASGoogle Scholar
• 84  Dhillon J, Allen BW, Hu YM, Coates AR, Mitchison DA: Metronidazole has no antibacterial effect in Cornell model murine tuberculosis. Int. J. Tuberc. Lung Dis.2,736–742 (1998).
  Medline CASGoogle Scholar
• 85  Hoff DR, Caraway ML, Brooks EJ et al.: Metronidazole lacks antibacterial activity in guinea pigs infected with Mycobacterium tuberculosis. Antimicrob. Agents Chemother.52,4137–4140 (2008).
  Medline CASGoogle Scholar
• 86  Klinkenberg LG, Sutherland LA, Bishai WR, Karakousis PC: Metronidazole lacks activity against Mycobacterium tuberculosis in an in vivo hypoxic granuloma model of latency. J. Infect. Dis.198,275–283 (2008).
  Medline CASGoogle Scholar
• 87  Dutt AK, Stead WW: Tuberculosis in the elderly. Med. Clin. North Am.77,1353–1368 (1993).
  Medline CASGoogle Scholar
• 88  Barry CE 3rd, Boshoff HI, Dartois V et al.: The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat. Rev. Microbiol.7,845–855 (2009).
  Medline CASGoogle Scholar
• 89  Tufariello JM, Chan J, Flynn JL: Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection. Lancet Infect. Dis.3,578–590 (2003).
  Medline CASGoogle Scholar
• 90  Chiang CY, Riley LW: Exogenous reinfection in tuberculosis. Lancet Infect. Dis.5,629–636 (2005).
  MedlineGoogle Scholar
• 91  Orme IM: The latent tuberculosis bacillus (I’ll let you know if I ever meet one). Int. J. Tuberc. Lung Dis.5,589–593 (2001).
  Medline CASGoogle Scholar
• 92  Gomez JE, McKinney JD: M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis (Edinb.)84,29–44 (2004).
  MedlineGoogle Scholar
• 93  Manabe YC, Bishai WR: Latent Mycobacterium tuberculosis-persistence, patience, and winning by waiting. Nat. Med.6,1327–1329 (2000).
  Medline CASGoogle Scholar
• 94  Smith DW, Balasubramanian V, Wiegeshaus E: A guinea pig model of experimental airborne tuberculosis for evaluation of the response to chemotherapy: the effect on bacilli in the initial phase of treatment. Tubercle72,223–231 (1991).
  Medline CASGoogle Scholar
• 95  Basaraba RJ, Bielefeldt-Ohmann H, Eschelbach EK et al.: Increased expression of host iron-binding proteins precedes iron accumulation and calcification of primary lung lesions in experimental tuberculosis in the guinea pig. Tuberculosis (Edinb.)88,69–79 (2008).
  Medline CASGoogle Scholar
• 96  Ojha AK, Baughn AD, Sambandan D et al.: Growth of Mycobacterium tuberculosis biofilms containing free mycolic acids and harbouring drug-tolerant bacteria. Mol. Microbiol.69,164–174 (2008).▪ Important study showing Mycobacterium tuberculosis can form biofilms.
  Medline CASGoogle Scholar
• 97  Beresford B, Sadoff JC: Update on research and development pipeline: tuberculosis vaccines. Clin. Infect. Dis.50(Suppl. 3),S178–S183 (2010).
  MedlineGoogle Scholar
• 98  Andersen P: TB vaccines: progress and problems. Trends Immunol.22,160–168 (2001).
  Medline CASGoogle Scholar
• 99  Kaufmann SH: Is the development of a new tuberculosis vaccine possible? Nat. Med.6,955–960 (2000).
  Medline CASGoogle Scholar
• 100  Orme IM: The search for new vaccines against tuberculosis. J. Leukoc. Biol.70,1–10 (2001).
  Medline CASGoogle Scholar
• 101  Orme IM, McMurray DN, Belisle JT: Tuberculosis vaccine development: recent progress. Trends Microbiol.9,115–118 (2001).
  Medline CASGoogle Scholar
• 102  Skeiky YA, Sadoff JC: Advances in tuberculosis vaccine strategies. Nat. Rev. Microbiol.4,469–476 (2006).
  Medline CASGoogle Scholar
• 103  Aagaard C, Hoang TT, Izzo A et al.: Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose. PLoS ONE4,E5930 (2009).
  MedlineGoogle Scholar
• 104  Skeiky YA, Alderson MR, Ovendale PJ et al.: Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J. Immunol.172,7618–7628 (2004).
  Medline CASGoogle Scholar
• 105  Brandt L, Skeiky YA, Alderson MR et al.: The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect. Immun.72,6622–6632 (2004).
  Medline CASGoogle Scholar
• 106  Reed SG, Coler RN, Dalemans W et al.: Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys. Proc. Natl Acad. Sci. USA106,2301–2306 (2009).
  Medline CASGoogle Scholar
• 107  Baldwin SL, Bertholet S, Kahn M et al.: Intradermal immunization improves protective efficacy of a novel TB vaccine candidate. Vaccine27,3063–3071 (2009).
  Medline CASGoogle Scholar
• 108  Bertholet S, Ireton GC, Kahn M et al.: Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis. J. Immunol.181,7948–7957 (2008).
  Medline CASGoogle Scholar
• 109  Coler RN, Dillon DC, Skeiky YA et al.: Identification of Mycobacterium tuberculosis vaccine candidates using human CD4⁺ T-cells expression cloning. Vaccine27,223–233 (2009).
  Medline CASGoogle Scholar
• 110  Bertholet S, Ireton GC, Ordway DJ et al.: A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug resistant Mycobacterium tuberculosis. Sci. Transl. Med.2(53),53ra74 (2010).
  MedlineGoogle Scholar
• 111  Orme IM: Current progress in tuberculosis vaccine development. Vaccine23,2105–2108 (2005).
  Medline CASGoogle Scholar
• 112  de Cassan SC, Pathan AA, Sander CR et al.: Investigating the induction of vaccine-induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG-immunized adults vaccinated with a new tuberculosis vaccine, MVA85A. Clin. Vaccine Immunol.17,1066–1073 (2010).
  Medline CASGoogle Scholar
• 113  Kolibab K, Yang A, Derrick SC, Waldmann TA, Perera LP, Morris SL: Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant. Clin. Vaccine Immunol.17,793–801 (2010).
  Medline CASGoogle Scholar
• 114  Sun R, Skeiky YA, Izzo A et al.: Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis. Vaccine27,4412–4423 (2009).
  Medline CASGoogle Scholar
• 115  Manca C, Tsenova L, Bergtold A et al.: Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-α /β. Proc. Natl Acad. Sci. USA98,5752–5757 (2001).
  Medline CASGoogle Scholar
• 116  Jeon BY, Derrick SC, Lim J et al.: Mycobacterium bovis BCG immunization induces protective immunity against nine different Mycobacterium tuberculosis strains in mice. Infect. Immun.76,5173–5180 (2008).
  Medline CASGoogle Scholar
• 117  Grode L, Seiler P, Baumann S et al.: Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette–Guerin mutants that secrete listeriolysin. J. Clin. Invest.115,2472–2479 (2005).
  Medline CASGoogle Scholar
• 118  van der Wel N, Hava D, Houben D et al.: M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid cells. Cell129,1287–1298 (2007).
  Medline CASGoogle Scholar
• 119  Park JS, Tamayo MH, Gonzalez-Juarrero M, Orme IM, Ordway DJ: Virulent clinical isolates of Mycobacterium tuberculosis grow rapidly and induce cellular necrosis but minimal apoptosis in murine macrophages. J. Leukoc. Biol.79,80–86 (2006).
  Medline CASGoogle Scholar
• 120  Magalhaes I, Sizemore DR, Ahmed RK et al.: rBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vector. PLoS ONE3,E3790 (2008).
  MedlineGoogle Scholar
• 121  Madakamutil LT, Christen U, Lena CJ et al.: CD8αα-mediated survival and differentiation of CD8 memory T cell precursors. Science304,590–593 (2004).
  Medline CASGoogle Scholar
• 122  Wang R, Natarajan K, Margulies DH: Structural basis of the CD8 α β/MHC class I interaction: focused recognition orients CD8 β to a T cell proximal position. J. Immunol.183,2554–2564 (2009).
  Medline CASGoogle Scholar
• 123  Cheroutre H, Lambolez F: Doubting the TCR coreceptor function of CD8αα. Immunity28,149–159 (2008).
  Medline CASGoogle Scholar
• 124  Abel B, Tameris M, Mansoor N et al.: The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4⁺ and CD8⁺ T cells in adults. Am. J. Respir. Crit. Care Med.181,1407–1417 (2010).
  Medline CASGoogle Scholar
• 125  Orme IM: The Achilles heel of BCG. Tuberculosis (Edinb.)90(6),329–332 (2010).
  Medline CASGoogle Scholar
• 126  Goldsack L, Kirman JR: Half-truths and selective memory: interferon γ, CD4⁺ T cells and protective memory against tuberculosis. Tuberculosis (Edinb.)87,465–473 (2007).
  Medline CASGoogle Scholar
• 127  Seder RA, Darrah PA, Roederer M: T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol.8,247–258 (2008).
  Medline CASGoogle Scholar
• 128  Kagina BM, Abel B, Scriba TJ et al.: Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis, following BCG vaccination of newborns. Am. J. Respir. Crit. Care Med.182(8),1073–1079 (2010).
  Medline CASGoogle Scholar
• 129  Lindenstrom T, Agger EM, Korsholm KS et al.: Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J. Immunol.182,8047–8055 (2009).
  Medline CASGoogle Scholar
• 130  Kraft SL, Dailey D, Kovach M et al.: Magnetic resonance imaging of pulmonary lesions in guinea pigs infected with Mycobacterium tuberculosis. Infect. Immun.72,5963–5971 (2004).
  Medline CASGoogle Scholar
• 131  Henao-Tamayo MI, Ordway DJ, Irwin SM, Shang S, Shanley C, Orme IM: Phenotypic definition of effector and memory T-lymphocyte subsets in mice chronically infected with Mycobacterium tuberculosis. Clin. Vaccine Immunol.17,618–625 (2010).
  Medline CASGoogle Scholar
• 132  Palanisamy G, DuTeau N, Eisenach K et al.: Clinical strains of Mycobacterium tuberculosis display a wide range of virulence in guinea pigs. Tuberculosis (Edinb.)89,203–209 (2009).
  MedlineGoogle Scholar
• 133  Palanisamy GS, Smith EE, Shanley CA, Ordway DJ, Orme IM, Basaraba RJ: Disseminated disease severity as a measure of virulence of Mycobacterium tuberculosis in the guinea pig model. Tuberculosis (Edinb.)88,295–306 (2008).
  MedlineGoogle Scholar
• 134  Green AM, Mattila JT, Bigbee CL, Bongers KS, Lin PL, Flynn JL: CD4⁺ regulatory T cells in a cynomolgus macaque model of Mycobacterium tuberculosis infection. J. Infect. Dis.202,533–541 (2010).
  Medline CASGoogle Scholar
• 135  Kremer K, van-der-Werf MJ, Au BK et al.: Vaccine-induced immunity circumvented by typical Mycobacterium tuberculosis Beijing strains. Emerg. Infect. Dis.15,335–339 (2009).
  MedlineGoogle Scholar
• 136  Cardona PJ, Asensio JG, Arbues A et al.: Extended safety studies of the attenuated live tuberculosis vaccine SO₂ based on phoP mutant. Vaccine27,2499–2505 (2009).
  Medline CASGoogle Scholar
• 137  Comas I, Chakravartti J, Small PM et al.: Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved. Nat. Genet.42,498–503 (2010).▪ Very important study showing bacterial epitopes are hyperconserved, which may confound vaccine design.
  Medline CASGoogle Scholar
• 138  Mackaness GB: The immunological basis of acquired cellular resistance. J. Exp. Med.120,105–120 (1964).
  Medline CASGoogle Scholar
• 139  Mackaness GB. Resistance to intracellular infection. J. Infect. Dis.123,439–445 (1971).
  Medline CASGoogle Scholar
• 140  Orme IM: Characteristics and specificity of acquired immunologic memory to Mycobacterium tuberculosis infection. J. Immunol.140,3589–3593 (1988).
  Medline CASGoogle Scholar
• 141  Orme IM: Induction of nonspecific acquired resistance and delayed-type hypersensitivity, but not specific acquired resistance in mice inoculated with killed mycobacterial vaccines. Infect. Immun.56,3310–3312 (1988).
  Medline CASGoogle Scholar
• 142  Orme IM, Andersen P, Boom WH: T cell response to Mycobacterium tuberculosis. J. Infect. Dis.167,1481–1497 (1993).
  Medline CASGoogle Scholar